trending Market Intelligence /marketintelligence/en/news-insights/trending/VLujxhInLKv9dKEFUWmFvQ2 content esgSubNav
In This List

Silence Therapeutics sues Alnylam, Medicines Co. in UK High Court

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook

Blog

The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism


Silence Therapeutics sues Alnylam, Medicines Co. in UK High Court

Silence Therapeutics plc filed a claim against Alnylam Pharmaceuticals Inc. and The Medicines Co. in the UK High Court to enforce its intellectual property rights on certain Alnylam products.

The claim asks the court to determine whether Silence is entitled to supplementary protection certificates over products including drugs Patisiran, Fitusiran, Givosiran and Inclisiran.

Supplementary protection certificates are intellectual property rights which can give up to five years of exclusivity after a patent expires.

Alnylam and Medicines Co. are jointly developing cholesterol-lowering drug Inclisiran. A phase 3 trial of Patisiran in treating a rare nerve disorder familial amyloid polyneuropathy recently met its main goal.

Fitusiran and Givosiran are early state drugs being developed for treating hemophilia and acute hepatic porphyrias, respectively.